| abstract |
the present invention consists of a system based on biopolymers, a crosslinking agent and stabilizing agents as an alternative to increase the bioavailability of therapeutic proteins after oral administration. it has an insulin encapsulation efficiency of about 70% and storage stability for 30 days. this formulation demonstrates the ability to protect about 64% of insulin in simulated gastric media (in vitro release test). thus, this formulation is able to protect protein drugs from acidic and enzymatic degradation in the gastrointestinal tract after oral administration, in addition to improving their permeability in the intestinal epithelium. |